ALURD · Allurion Technologies, Inc.
$4.36
-0.19 (-4.18%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's recurring losses from operations incurred since inception, its expectation of continuing operating losses for the foreseeable future, the potential need to raise additional capital to finance its future operations, and noncompliance with certain financial covenants under its credit facilities, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued.”View the 10-Q filed May 15, 2026
Market Cap
$68.28M
Shares
15.01M
Allurion Technologies, Inc. Earnings Call Transcripts
Every quarterly earnings call for Allurion Technologies, Inc. (ALURD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
Earnings call
FY25 · Q3
2025-11-12
Allurion Technologies, Inc. Q3 FY2025 Earnings Call
Confident tone
Strategic pivot to combination therapy with GLP-1s
U.S. market launch preparation
FDA approval progress
Revenue
$2.66M
▼ 50.5% YoY Diluted EPS
$-22.95
▼ 145% YoY Gross margin
49.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Allurion Technologies, Inc. Q2 FY2025 Earnings Call
Positive tone
R&D pipeline and GLP-1 drug-eluting balloon
Strategic pivot to combination therapy with low-dose GLP-1s
Operating expense reduction and restructuring
Revenue
$3.38M
▼ 71.3% YoY Diluted EPS
$-19.20
Gross margin
73.9%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2025-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q1
2025-05-14
Allurion Technologies, Inc. Q1 FY2025 Earnings Call
Confident tone
GLP-1 Combination Strategy
FDA Approval Pathway
Path to Profitability
Revenue
$5.58M
▼ 40.5% YoY Diluted EPS
$-4.65
▼ 132.3% YoY Gross margin
74.6%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-26
Allurion Technologies, Inc. Q4 FY2024 Earnings Call
Revenue
$5.59M*
Gross margin
45.3%
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2025-03-03
TD Cowen's 45th Annual Health Care Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q3
2024-11-13
Allurion Technologies, Inc. Q3 FY2024 Earnings Call
Positive tone
Q3 Financial Results and France Recall
GLP-1 Market Impact and Combination Therapy
U.S. FDA Approval and Launch
Revenue
$5.37M
▼ 70.5% YoY Diluted EPS
$51.00
Gross margin
58.0%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Allurion Technologies, Inc. Q2 FY2024 Earnings Call
Balanced tone
France ANSM suspension
GLP-1 competition and positioning
Procedure volume and demand
Revenue
$11.77M
▼ 9.2% YoY Diluted EPS
$-65.10
Gross margin
76.4%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Allurion Technologies, Inc. Q1 FY2024 Earnings Call
Confident tone
Revenue and 2024 guidance
Virtual Care Suite / B2B SaaS
Geographic expansion and AUDACITY FDA trial
Revenue
$9.39M
Diluted EPS
$14.40
Gross margin
73.2%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Allurion Technologies, Inc. Q4 FY2023 Earnings Call
Positive tone
GLP-1 drugs as opportunity and headwind
Cost reduction and cash burn
Audacity FDA trial and PMA
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Allurion Technologies, Inc. Q3 FY2023 Earnings Call
Revenue
$18.20M
Diluted EPS
$-202.50
Gross margin
76.7%
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Showing 1–11 of 11 earnings calls